

Supplementary References

- S1. Association AP. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC2013.
- S2. McElroy SL, Keck Jr PE, Pope Jr HG, et al. Compulsive buying: A report of 20 cases. *J Clin Psychiatry* 1994;55(6):242-48.
- S3. Kovács M, Makkos A, Pintér D, et al. Screening for problematic Internet use may help identify impulse control disorders in Parkinson's disease. *Behav Neurol* 2019;2019. doi: 10.1155/2019/4925015
- S4. Weintraub D. Impulse control disorders in Parkinson's disease: A 20-year odyssey. *Mov Disord* 2019;34(4):447-52. doi: 10.1002/mds.27668
- S5. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. *Nature* 1990;347(6289):146-51. doi: 10.1038/347146a0
- S6. Palminteri S, Lebreton M, Worbe Y, et al. Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes. *Proc Natl Acad Sci U S A* 2009;106(45):19179-84. doi: 10.1073/pnas.0904035106
- S7. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *Journal of Pharmacology and Experimental Therapeutics* 2002;303(2):791-804. doi: 10.1124/jpet.102.039867
- S8. Rokosik SL, Napier TC. Pramipexole-induced increased probabilistic discounting: Comparison between a rodent model of parkinson's disease and controls. *Neuropsychopharmacology* 2012;37(6):1397-408. doi: 10.1038/npp.2011.325
- S9. Zengin Y, Authier N, Llorca PM, et al. Do dopaminergic drugs induce a place preference in normal rat? *Parkinsonism Relat Disord* 2009;15. doi: 10.1016/S1353-8020(09)70446-8
- S10. Cenci MA, Francardo V, O'Sullivan SS, et al. Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached? *Neurobiol Dis* 2015;82. doi: 10.1016/j.nbd.2015.08.026
- S11. Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. *J Neurol Neurosurg Psychiatry* 2016;87(8):864-70. doi: 10.1136/jnnp-2015-311827
- S12. Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson's disease: Recent advances. *Current Opinion in Neurology* 2011;24(4):324-30. doi: 10.1097/WCO.0b013e3283489687
- S13. Ye Z, Altena E, Nombela C, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. *BRAIN* 2014;137(4):1145-55. doi: 10.1093/brain/awu032
- S14. Ye Z, Altena E, Nombela C, et al. Improving response inhibition in Parkinson's disease with atomoxetine. *Biol Psychiatry* 2015;77(8):740-48. doi: 10.1016/j.biopsych.2014.01.024
- S15. Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study. *Neurology* 2014;83(9):826-33. doi: 10.1212/WNL.0000000000000729

- S16. Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in parkinson disease is reduced by amantadine. *Annals of Neurology* 2010;68(3):400-04. doi: 10.1002/ana.22029
- S17. Cera N, Bifolchetti S, Martinotti G, et al. Amantadine and cognitive flexibility: Decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. *Neuropsychiatr Dis Treat* 2014;10. doi: 10.2147/NDT.S54423
- S18. Lee JY, Kim HJ, Jeon BS. Is pathological gambling in Parkinson's disease reduced by amantadine? *Annals of Neurology* 2011;69(1):213-14. doi: 10.1002/ana.22289
- S19. Cardinal RN, Parkinson JA, Hall J, et al. Emotion and motivation: The role of the amygdala, ventral striatum, and prefrontal cortex. *Neuroscience and Biobehavioral Reviews* 2002;26(3):321-52. doi: 10.1016/S0149-7634(02)00007-6
- S20. Tessitore A, Santangelo G, De Micco R, et al. Cortical thickness changes in patients with Parkinson's disease and impulse control disorders. *Parkinsonism Relat Disord* 2016;24. doi: 10.1016/j.parkreldis.2015.10.013
- S21. Cerasa A, Salzone M, Nigro S, et al. Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling. *Parkinsonism Relat Disord* 2014;20(11):1209-14. doi: 10.1016/j.parkreldis.2014.09.001
- S22. Valentin VV, Dickinson A, O'Doherty JP. Determining the neural substrates of goal-directed learning in the human brain. *J Neurosci* 2007;27(15):4019-26. doi: 10.1523/JNEUROSCI.0564-07.2007
- S23. Van Eimeren T, Pellecchia G, Cilia R, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. *Neurology* 2010;75(19):1711-16. doi: 10.1212/WNL.0b013e3181fc27fa
- S24. Golchert J, Smallwood J, Jefferies E, et al. In need of constraint: Understanding the role of the cingulate cortex in the impulsive mind. *NeuroImage* 2017;146:804-13. doi: <https://doi.org/10.1016/j.neuroimage.2016.10.041>
- S25. Ricciardi L, Lambert C, De Micco R, et al. Can we predict development of impulsive-compulsive behaviours in Parkinson's disease? *Journal of neurology, neurosurgery, and psychiatry* 2018;89(5):476-81. doi: 10.1136/jnnp-2017-317007
- S26. Canu E, Agosta F, Markovic V, et al. White matter tract alterations in Parkinson's disease patients with punding. *Parkinsonism Relat Disord* 2017;43. doi: 10.1016/j.parkreldis.2017.07.025
- S27. Imperiale F, Agosta F, Canu E, et al. Brain structural and functional signatures of impulse control disorder in Parkinson's disease. *Neurodegenerative Dis* 2017;17((Imperiale F.; Agosta F.; Canu E.; Basaia S.; Filippi M.) San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Institute of Experimental Neurology, Milan, Italy):1538.
- S28. Donders FC. On the speed of mental processes. *Acta psychologica* 1969;30:412-31.
- S29. Logan GD, Cowan WB, Davis KA. On the ability to inhibit simple and choice reaction time responses: a model and a method. *Journal of experimental psychology Human perception and performance* 1984;10(2):276-91.
- S30. Zois E, Kortlang N, Vollstädt-Klein S, et al. Decision-making deficits in patients diagnosed with disordered gambling using the Cambridge Gambling task: The effects

- of substance use disorder comorbidity. *Brain Behav* 2014;4(4):484-94. doi: 10.1002/brb3.231
- S31. Waters-Wood SM, Xiao L, Denburg NL, et al. Failure to learn from repeated mistakes: Persistent decision-making impairment as measured by the iowa gambling task in patients with ventromedial prefrontal cortex lesions. *J Int Neuropsychol Soc* 2012;18(5):927-30. doi: 10.1017/S135561771200063X
- S32. Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. *Journal of experimental psychology General* 1999;128(1):78-87.
- S33. Clark L, Robbins TW, Ersche KD, et al. Reflection Impulsivity in Current and Former Substance Users. *Biol Psychiatry* 2006;60(5):515-22. doi: 10.1016/j.biopsych.2005.11.007
- S34. Chaytor N, Schmitter-Edgecombe M. The ecological validity of neuropsychological tests: A review of the literature on everyday cognitive skills. *Neuropsychology Review* 2003;13(4):181-97. doi: 10.1023/B:NERV.0000009483.91468.fb
- S35. Reid-Arndt SA, Nehl C, Hinkebein J. The Frontal Systems Behaviour Scale (FrSBe) as a predictor of community integration following a traumatic brain injury. *Brain Injury* 2007;21(13-14):1361-69. doi: 10.1080/02699050701785062
- S36. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. *Journal of Clinical Psychology* 1995;51(6):768-74.
- S37. Vitale C, Santangelo G, Trojano L, et al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. *Mov Disord* 2011;26(5):830-36. doi: 10.1002/mds.23567
- S38. Cloninger CR. A systematic method for clinical description and classification of personality variants: A proposal. *Archives of General Psychiatry* 1987;44(6):573-88.
- S39. Ricciardi L, Haggard P, de Boer L, et al. Acting without being in control: Exploring volition in Parkinson's disease with impulsive compulsive behaviours. *Parkinsonism Relat Disord* 2017;40:51-57. doi: <https://doi.org/10.1016/j.parkreldis.2017.04.011>
- S40. Tomer R, Aharon-Peretz J. Novelty seeking and harm avoidance in Parkinson's disease: Effects of asymmetric dopamine deficiency. *J Neurol Neurosurg Psychiatry* 2004;75(7):972-75. doi: 10.1136/jnnp.2003.024885
- S41. Valença GT, Glass PG, Negreiros NN, et al. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. *Parkinsonism Relat Disord* 2013;19(7):698-700. doi: 10.1016/j.parkreldis.2013.03.004
- S42. Martínez-Horta S, Riba J, de Bobadilla RF, et al. Apathy in parkinson's disease: Neurophysiological evidence of impaired incentive processing. *J Neurosci* 2014;34(17):5918-26. doi: 10.1523/JNEUROSCI.0251-14.2014
- S43. Thobois S, Lhommée E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. *BRAIN* 2013;136(5):1568-77. doi: 10.1093/brain/awt067
- S44. Muhammed K, Manohar S, Ben Yehuda M, et al. Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson's disease. *BRAIN* 2016;139(10):2706-21. doi: 10.1093/brain/aww188

- S45. Fantini ML, Figorilli M, Arnulf I, et al. Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder. *J Neurol Neurosurg Psychiatry* 2018;89(3):305-10. doi: 10.1136/jnnp-2017-316576
- S46. Rodríguez LB, Violante MR, Arriaga AC, et al. Lack of association between impulse control disorders and REM sleep behavior disorder in patients with Parkinson's disease. *Arch Neurocienc* 2016;21(4):16-21.
- S47. Bayard S, Dauvilliers Y, Yu H, et al. Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. *Parkinsonism Relat Disord* 2014;20(12):1411-14. doi: 10.1016/j.parkreldis.2014.09.020
- S48. Riley M, Bakeberg M, Byrnes M, et al. Demographic and Clinical Predictors of Trait Impulsivity in Parkinson's Disease Patients. *Parkinson's Dis* 2018;2018. doi: 10.1155/2018/9472120
- S49. Barry DT, Stefanovics EA, Desai RA, et al. Gambling problem severity and psychiatric disorders among Hispanic and white adults: Findings from a nationally representative sample. *J Psychiatr Res* 2011;45(3):404-11. doi: 10.1016/j.jpsychires.2010.07.010
- S50. Volberg RA, Abbott MW, Rönnerberg S, et al. Prevalence and risks of pathological gambling in Sweden. *Acta Psychiatr Scand* 2001;104(4):250-56. doi: 10.1034/j.1600-0447.2001.00336.x
- S51. Group PDMEDC. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. *Lancet* 2014;384(9949):1196-205. doi: doi:10.1016/S0140-6736(14)60683-8
- S52. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in parkinson disease. *Archives of Neurology* 2010;67(1):58-63. doi: 10.1001/archneurol.2009.294
- S53. Lim S-Y, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punning after deep brain stimulation surgery for Parkinson's disease. *J Clin Neurosci* 2009;16(9):1148-52. doi: 10.1016/j.jocn.2008.12.010
- S54. Ávila A, Cardona X, Martín-Baranera M, et al. Impulsive and compulsive behaviors in Parkinson's disease: A one-year follow-up study. *Journal of the Neurological Sciences* 2011;310(1-2):197-201. doi: 10.1016/j.jns.2011.05.044
- S55. Martinez-Martin P, Rodriguez-Blazquez C, Catalan MJ. Independent and Complementary Validation of the QUIP-RS in Advanced Parkinson's Disease. *Mov Disord Clin Pract* 2018;5(3):341-42. doi: 10.1002/mdc3.12603
- S56. Probst CC, Winter LM, Möller B, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. *Journal of Neurology* 2014;261(5):936-42. doi: 10.1007/s00415-014-7299-6
- S57. Lhommée E, Wojtecki L, Czernecki V, et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. *Lancet Neurol* 2018;17(3):223-31. doi: 10.1016/S1474-4422(18)30035-8

- S58. Rieu I, Martinez-Martin P, Pereira B, et al. International validation of a behavioral scale in Parkinson's disease without dementia. *Mov Disord* 2015;30(5):705-13. doi: 10.1002/mds.26223
- S59. Izzo VA, Donati MA, Ramat S, et al. Impulse control disorders in Parkinson's disease: A systematic review on the psychometric properties of the existing measures. *PLoS ONE* 2019;14(6) doi: 10.1371/journal.pone.0217700
- S60. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease : The AMANDYSK trial. *Neurology* 2014;82(4):300-07. doi: 10.1212/WNL.0000000000000050
- S61. Kehagia AA, Housden CR, Regenthal R, et al. Targeting impulsivity in Parkinson's disease using atomoxetine. *BRAIN* 2014;137(7):1986-97. doi: 10.1093/brain/awu117
- S62. Warren N, O'Gorman C, Lehn A, et al. Dopamine dysregulation syndrome in Parkinson's disease: A systematic review of published cases. *J Neurol Neurosurg Psychiatry* 2017;88(12):1060-64. doi: 10.1136/jnnp-2017-315985
- S63. NICE TNIfHaCE. Parkinson's disease in adults. 2019
- S64. Kasemsuk C, Oyama G, Hattori N. Management of impulse control disorders with deep brain stimulation: A double-edged sword. *Journal of the Neurological Sciences* 2017;374((Kasemsuk C.; Oyama G., g_oyama@juntendo.ac.jp; Hattori N.) Department of Neurology, Juntendo University, Faculty of Medicine, Tokyo, Japan):63-68. doi: 10.1016/j.jns.2017.01.019
- S65. Abbes M, Lhommée E, Thobois S, et al. Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: Results from a long-term follow-up cohort study. *J Neurol Neurosurg Psychiatry* 2018;89(8):836-43. doi: 10.1136/jnnp-2017-316373
- S66. Jahanshahi M, Obeso I, Baunez C, et al. Parkinson's disease, the subthalamic nucleus, inhibition, and impulsivity. *Mov Disord* 2015;30(2):128-40. doi: 10.1002/mds.26049
- S67. Castrioto A, Lhommée E, Moro E, et al. Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. *Lancet Neurol* 2014;13(3):287-305. doi: 10.1016/S1474-4422(13)70294-1
- S68. Broen M, Duits A, Visser-Vandewalle V, et al. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: A review. *Parkinsonism Relat Disord* 2011;17(6):413-17. doi: 10.1016/j.parkreldis.2011.02.013
- S69. Mosley PE, Smith D, Coyne T, et al. The site of stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for Parkinson's disease. *NeuroImage Clin* 2018;18. doi: 10.1016/j.nicl.2018.03.009
- S70. Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. *Mov Disord* 2009;24(12):1803-10. doi: 10.1002/mds.22678
- S71. Krishnamoorthy S, Rajan R, Banerjee M, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. *Parkinsonism Relat Disord* 2016;30((Krishnamoorthy S., soumyamoorthy.k@gmail.com; Rajan R., roops84@gmail.com; Kumar H., hardeep@sctimst.ac.in; Sarma G., sarmasg24@yahoo.com; Krishnan S., drsyam@sctimst.ac.in; Kishore A., asha@sctimst.ac.in) Comprehensive Care Centre

for Movement Disorders, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India):13-17. doi: 10.1016/j.parkreldis.2016.06.005

- S72. Zainal Abidin S, Tan EL, Chan SC, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients. *BMC Neurol* 2015;15(1) doi: 10.1186/s12883-015-0316-2
- S73. McDonnell KE, van Wouwe NC, Harrison MB, et al. Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease. *Brain Behav* 2018;8(7) doi: 10.1002/brb3.1008
- S74. Redenšek S, Flisar D, Kojovic M, et al. Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's disease. *Front Pharmacol* 2019;9(JAN) doi: 10.3389/fphar.2019.00008
- S75. Vallelunga A, Flaibani R, Formento-Dojot P, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. *Parkinsonism Relat Disord* 2012;18(4):397-99. doi: 10.1016/j.parkreldis.2011.10.019
- S76. Lee JY, Jeon BS, Kim HJ, et al. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. *Parkinsonism Relat Disord* 2012;18(1):76-78. doi: 10.1016/j.parkreldis.2011.08.009